Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 51Terminated 20Recruiting 13Unknown 6Active not recruiting 6Not yet recruiting 3Withdrawn 2

Sponsor Class

OTHER 10INDUSTRY 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Gynecologic 1

Conditions

Recurrence 1Ovarian Neoplasms 1Multiple Myeloma 1

Interventions

Paclitaxel 31Cyclophosphamide 30Cisplatin 29Bevacizumab 28Carboplatin 27Fluorouracil 24pembrolizumab 21Nivolumab 21Leucovorin 20Rituximab 19avelumab 18Gemcitabine 18Docetaxel 18Dexamethasone 18Capecitabine 17ALT-803 15130-nm albumin-bound paclitaxel 14Oxaliplatin 12Cetuximab 12fludarabine 11Ipilimumab 11venetoclax 10atezolizumab 10Radiosurgery 10Radiotherapy 9Pemetrexed 9Omacor 9Lenalidomide 9Bendamustine Hydrochloride 9yeast-CEA vaccine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × INDUSTRY × liposomal doxorubicin × Clear all
NCT00706953 2015-04-06

A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

NCT00610792 2009-07-14

Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens

Millennium Pharmaceuticals, Inc.

Phase 2 Withdrawn
91 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡